(Press-News.org) (ORLANDO, Dec. 6, 2025) Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health. Among patients with a mutation in their cancer cells that is generally associated with more favorable outcomes from AML treatment, survival for Black patients was less than half that of white patients.
“To our knowledge, this study includes data for a larger number of Black patients than any other such study of AML survival across NCI-supported clinical trials,” said study first author Shella Saint Fleur-Lominy, MD, PhD, an associate professor of medicine at the University of Maryland School of Medicine and a member of the cancer therapeutics program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. “Our findings confirm those of previous, smaller studies that Black patients with AML develop the disease at a significantly younger age, on average, than white patients and, even when treated in clinical trials, have significantly worse outcomes than white patients.”
AML is a rare, fast-growing cancer that starts in the bone marrow, the soft tissue inside bones where blood cells form. Early blood-forming cells change (mutate) and begin to grow out of control, resulting in large numbers of abnormal, immature blood cells that spill into the bloodstream and crowd out healthy cells. As a result, AML can cause organs to stop working properly and make the body very sick. Doctors base treatment recommendations on biopsy tests that identify the “profile” of mutations in a patient’s AML cells because different drugs can target different mutations, leading to better responses to treatment and longer survival.
Years of published reports have shown poorer outcomes for Black patients treated for AML compared with white patients, Dr. Saint Fleur-Lominy said; the reasons for this disparity are not completely understood. In one recent study, Black patients diagnosed in their teens or under age 40 had worse outcomes than their white counterparts even when they had mutations that, in white patients, are usually associated with more favorable treatment outcomes.
Clinical trials often allow patients with cancer to access novel therapies for their disease before they become widely available. After decades of efforts to promote access to clinical trials for patients of all backgrounds, a 2020 report showed an increase in the number of Black patients in trials supported by the NCI. A related study found a higher rate of Black patients in NCI-sponsored trials than in pharmaceutical company trials. Still, Black patients remain underrepresented in many clinical trials, Dr. Saint Fleur-Lominy said.
In this study, she and her colleagues reviewed the medical records of all patients with newly diagnosed AML who were enrolled in 10 ECOG-ACRIN Cancer Research Group clinical trials between 1984 and 2019 (ECOG-ACRIN is a member of the NCI’s National Clinical Trials Network). The research team then compared white and Black patients’ overall survival (i.e., death from any cause), disease-free survival (i.e., the length of time after treatment during which a patient has no signs of the disease returning), and the genetic mutations found in their cancer cells.
They collected data for a total of 3,469 white patients, 184 Black patients, and 156 patients of other races and ethnicities. Across the 10 trials, the proportion of Black patients enrolled ranged from around 1% to 11%. The median age of Black patients at AML diagnosis was 47.9 years, compared with 53.5 years for white patients, a statistically significant difference. Moreover, compared with white patients, Black patients had a 31.3% higher risk of dying from AML and 21.2% higher risk of dying from any cause.
Results showed that the most common mutations seen in AML cells occurred at similar rates in Black and white patients. However, among patients with a mutation in one particular gene, known as NPM1, the analysis found a significant difference in overall survival, with Black patients surviving for a median of 8.9 months compared with 19.1 months for white patients.
“Although the NPM1 mutation is typically associated with more favorable outcomes of AML treatment, we did not see those more favorable outcomes in Black patients,” said Dr. Saint Fleur-Lominy.
While similar numbers of Black and white patients overall received transplants of blood-forming stem cells, fewer Black patients (37.1%) than white patients (48.5%) received stem cells from a healthy, compatible donor. This type of transplant offers patients with high-risk AML the best chance of a cure, Dr. Saint Fleur-Lominy said. The alternative, collecting the patient’s own stem cells and reinfusing them after high-dose chemotherapy, is no longer considered a standard treatment for AML in the United States, she added.
A limitation of the study, she said, is that data on patients’ mutations profiles are less comprehensive than she and her team would have liked. The study includes data for patients treated across four decades, she said, and the advanced technology now available to perform such testing did not exist when clinical trials of AML treatment were conducted in earlier decades.
As a next step, Dr. Saint Fleur-Lominy said that she would like to see the data from this study combined with other data sets of patients with AML to increase the number of patients with comprehensive genetic data and confirm whether the association of certain genetic mutations with AML outcomes differs in Black patients compared with white patients.
This study was conducted by the ECOG-ACRIN Cancer Research Group and supported by the NCI.
Shella Saint Fleur-Lominy, MD, PhD, of the University of Maryland School of Medicine, will present this study on Saturday, December 6, 2025, at 2:15 p.m. Eastern time in W415A (Valencia Room) of the Orange County Convention Center.
###
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. Join the #Fight4Hematology by visiting hematology.org/fight4hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematologic research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
END
Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients
2025-12-06
ELSE PRESS RELEASES FROM THIS DATE:
Emergency departments fall short on delivering timely treatment for sickle cell pain
2025-12-06
(ORLANDO, Dec. 6, 2025) A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications within the first hour as recommended by the American Society of Hematology (ASH) and National Heart, Lung, and Blood Institute (NHLBI).
Based on data from several hundred medical centers across the United States, the research represents the first large, national study to assess guideline adherence across diverse EDs. It shows substantially ...
Study shows no clear evidence of harm from hydroxyurea use during pregnancy
2025-12-06
(ORLANDO, Dec. 6, 2025) Taking the sickle cell drug hydroxyurea during or shortly before pregnancy does not appear to cause specific issues in newborns, according to the first prospective study of pregnancies involving hydroxyurea exposure.
Since there may yet be undocumented effects, the authors still recommend discontinuing the drug before pregnancy, if possible. However, the findings offer reassurance that hydroxyurea exposure may not cause harm when unplanned pregnancies occur or when the drug is the only or best option ...
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
2025-12-06
(ORLANDO, Dec. 6, 2025) Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study. The study included over 1,000 patients, representing the largest and most comprehensive analysis of long-term transplant outcomes to date in people living with sickle cell disease.
“A majority of patients in this cohort are alive; the transplant worked so they no longer show symptoms of their sickle cell disease, and most have had no late effects post-transplant,” said lead study author Elizabeth Stenger, ...
Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia
2025-12-06
(ORLANDO, Dec. 6, 2025) The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers prepare to meet growing demand for gene therapies in the coming years.
“Gene therapy requires system-level coordination and close collaboration across patients, treatment centers, payers, and manufacturers,” said study author Joanne Lager, MD, chief medical officer at Genetix Biotherapeutics Inc. “The demand for these one-time durable gene ...
Early results suggest exa-cel gene therapy works well in children
2025-12-06
(ORLANDO, Dec. 6, 2025) Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. Researchers say the therapy’s potential to offer a cure at an early age – before organ damage accumulates – could make exa-cel even more beneficial in children than adults.
“All younger patients with sufficient follow-up met the primary endpoint of being transfusion independent in those with beta thalassemia and free of vaso-occlusive crises for those with sickle cell disease,” said ...
NTIDE: Disability employment holds steady after data hiatus
2025-12-05
East Hanover, NJ – December 5, 2025 – The December 2025 National Trends in Disability Employment (nTIDE) report shows that employment outcomes for working-aged people with disabilities remain near historic highs, despite broader economic uncertainty. nTIDE reporting was on hiatus while the federal government shutdown delayed the release of employment data, which only recently became available.
Although employment and labor force participation edged down slightly in September, both measures continue to outperform year-to-year trends for workers without disabilities. Overall, the findings point to sustained labor market engagement among people with disabilities, ...
Social lives of viruses affect antiviral resistance
2025-12-05
Interactions among viruses can help them succeed inside their hosts or impart vulnerabilities that make them easier to treat. Scientists are learning the ways viruses mingle inside the cells they infect, as well as the consequences of their socializing.
Ph.D. student Alexander J. Robertson in the Molecular & Cellular Biology program at the University of Washington is among those scientists.
“I study the evolution of antimicrobial resistance through mechanisms which require interaction between microbes,” he explained.
This week he is the lead author of a paper in Nature Ecology & Evolution on that topic.
Polioviruses ...
Dose of psilocybin, dash of rabies point to treatment for depression
2025-12-05
ITHACA, N.Y. – An international collaboration led by Cornell University researchers used a combination of psilocybin and the rabies virus to map how – and where – the psychedelic compound rewires the connections in the brain.
Specifically, they showed psilocybin weakens the cortico-cortical feedback loops that can lock people into negative thinking. Psilocybin also strengthens pathways to subcortical regions that turn sensory perceptions into action, essentially enhancing sensory-motor responses.
The ...
Helping health care providers navigate social, political, and legal barriers to patient care
2025-12-05
In November, The Lancet, one of the world’s most esteemed medical journals, launched a new monthly series of case studies that goes beyond clinical diagnoses to illuminate the social and cultural forces that contribute to each patient’s condition.
Clinical case studies have long been a fixture in medical journals and are a primary way doctors and other health professionals continue learning after their initial training. Typically, case studies are short summaries of a patient’s predicament alongside a clinician’s assessment, diagnosis, ...
Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments
2025-12-05
Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments
Advises that injectable treatments must be offered, reducing reliance on opioids
PHOENIX – A new study by Phoenix’s Barrow Neurological Institute and the University of Calgary has found which injectable treatments showed the most benefit for migraine patients and should be routinely offered by Emergency Departments (ED) when feasible. The findings from the study will update the guidelines for the American Headache Society.
Based on a systematic review of clinical trial data, the study ...